Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
We performed a retrospective observational study to examine the incidence of invasive aspergillosis (IA) among allogeneic hematopoietic stem cell transplant (HSCT) recipients, according to whether patients received at least 1 week of voriconazole prophylaxis. We report no cases of IA among 92 HSCT recipients who received voriconazole prophylaxis compared with a 10% (23/223) incidence among those receiving other systemic antifungals for prophylaxis (P < .0005).
Siwek
Gregory T
GT
Program of Hospital Epidemiology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
Pfaller
Michael A
MA
Polgreen
Philip M
PM
Cobb
Sandra
S
Hoth
Peter
P
Magalheas-Silverman
Margarida
M
Diekema
Daniel J
DJ
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000453:epidemiology / Q000517:prevention & control*; D016009:Chi-Square Distribution; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole